[This Week's Paid-in Capital Increase] Public Offering Schedule for the Fourth Week of April

[Asia Economy Reporter Hyunseok Yoo] This month (April) in the fourth week, Jaes&D and Medicox will proceed with rights offerings.

◆Jaes&D=Jaes&D will conduct subscription for existing shareholders and employee stock ownership associations from the 26th to the 27th, and general public subscription from the 29th to the 30th of the same month. Through this rights offering, 12 million shares will be issued. This corresponds to approximately 44.81% of the total issued shares of 26,782,520. The fixed issue price is 9,160 KRW. The company will raise 109.92 billion KRW through the rights offering. All the raised funds will be used for operating capital. They are planned to be used for land acquisition for housing development projects.

Jaes&D is a company mainly engaged in real estate services and construction. Specifically, it operates PM businesses such as real estate lease management and private investment project management services, information and communication businesses including electricity and Internet of Things (IoT), and CS businesses such as facility maintenance services including apartment move-in management and customer center operations. Through its housing development business division, it also engages in construction and real estate development sales. Last year, its sales and operating profit were 356.2 billion KRW and 27.3 billion KRW respectively, representing increases of 28.2% and 22% compared to the previous year.

◆Medicox=Medicox will conduct subscription for existing shareholders and oversubscription from the 30th of this month to the 3rd of next month. Then, from May 6th to 7th, it will conduct a public offering subscription in Japan. Through this rights offering, a total of 21.5 million shares will be issued. The fixed issue price is 1,070 KRW, and a total of 23.05 billion KRW will be raised. Of the raised funds, 15.75448 billion KRW will be used for debt repayment. Additionally, 768.4 million KRW will be allocated for facility funds, and 5.77148 billion KRW will be invested in operating capital.

Medicox’s predecessor was Jungang Ocean. The company changed its name last year. It is engaged in bio and ship parts manufacturing. Last year, on a consolidated basis, it recorded sales of 16.2 billion KRW and an operating loss of 4.3 billion KRW. Sales increased by 56.38% compared to the previous year, but operating losses continued.

This content was produced with the assistance of AI translation services.